Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: The role of pharmacogenetics and pharmacokinetics

Drug Discovery Today

Volumn 19, Issue 10, 2014, Pages 1572-1586

  Ten Brink, M H ^a   Zwaveling, J ^a   Swen, J J ^a   Bredius, R G M ^a   Lankester, A C ^a   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; HYDROXYUREA; ITRACONAZOLE; MELPHALAN; METRONIDAZOLE; PARACETAMOL; PHENYTOIN; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; ALKYLATING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; APLASTIC ANEMIA; AREA UNDER THE CURVE; BETA THALASSEMIA; BLEEDING; CHILD; COMPARTMENT MODEL; DIAPER DERMATITIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; ENGRAFTMENT; GASTROINTESTINAL TOXICITY; GONAD DYSFUNCTION; GRAFT VERSUS HOST REACTION; GROWTH RETARDATION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERPARATHYROIDISM; HYPOTHYROIDISM; INFECTION; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG INJURY; LUNG TOXICITY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MICROANGIOPATHY; MUCOSA INFLAMMATION; MYCOSIS; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PNEUMONIA; PROMYELOCYTIC LEUKEMIA; REVIEW; SEIZURE; SICKLE CELL ANEMIA; SKIN TOXICITY; TANDEM MASS SPECTROMETRY; THALASSEMIA MAJOR; VIRUS INFECTION; VOLUME OF DISTRIBUTION; WHOLE BODY RADIATION; ANALOGS AND DERIVATIVES; ANIMAL; GENETIC POLYMORPHISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; DRUG MONITORING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDIVIDUALIZED MEDICINE; POLYMORPHISM, GENETIC;

EID: 84908641697     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.04.005     Document Type: Review

References (106)

1. Sisler, I.Y. et al. (2009) Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study. Biol. Blood Marrow Transplant. 15, 1620-1627
2. Shaw, P.J. et al. (2010) Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 116, 4007-4015
3. Davies, S.M. et al. (2000) Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J. Clin. Oncol. 18, 340-347
4. Haddow, A. and Timmis, G.M. (1953) Myleran in chronic myeloid leukaemia; chemical constitution and biological action. Lancet 264, 207-208
5. Santos, G.W. and Tutschka, P.J. (1974) Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J. Natl. Cancer Inst. 53, 1781-1785
6. Wachowiak, J. et al. (2002) Intravenous treosulfan in conditioning before allogeneic HSCT from MSD in children with high risk of toxic complications related to conventional preparative regimen. Bone Marrow Transplant. 30, S12
7. Feit, P.W. et al. (1970) Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate. J. Med. Chem. 13, 1173-1175
8. Hartley, J.A. et al. (1999) DNA alkylation and interstrand cross-linking by treosulfan. Br. J. Cancer 79, 264-266
9. Sjöö, F. et al. (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp. Hematol. 34, 115-121
10. Munkelt, D. et al. (2008) Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother. Pharmacol. 62, 821-830
11. Casper, J. et al. (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J. Clin. Oncol. 28, 3344-3351
12. Wachowiak, J. et al. (2011) Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 46, 1510-1518
13. Główka, F.K. et al. (2010) High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert Opin. Investig. Drugs 19, 1275-1295
14. Slatter, M.A. et al. (2011) Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 117, 4367-4375
15. Bernardo, M.E. et al. (2012) Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 120, 473-476
16. Mathews, V. et al. (2013) Improved clinical outcomes of high risk β Thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS ONE 8, e61637
17. Choudhary, D. et al. (2013) Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Biol. Blood Marrow Transplant. 19, 492-495
18. Otsuka America Pharmaceutical, Inc., (2011) BUSULFEX(R) IV injection, busulfan IV injection. Otsuka America Pharmaceutical, Inc., Rockville, MD
19. Willson, J.K. (1978) Pulmonary toxicity of antineoplastic drugs. Cancer Treat. Rep. 62, 2003-2008
20. Bearman, S.I. (2000) Veno-occlusive disease of the liver. Curr. Opin. Oncol. 12, 103-109
21. McDonald, G.B. et al. (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann. Intern. Med. 118, 255-267
22. McDonald, G.B. et al. (1984) Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4, 116-122
23. Ansari, M. et al. (2013) Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. Bone Marrow Transplant. 48, 939-946
24. Grochow, L.B. et al. (1989) Pharmacokinetics of busulfan: correlation with venoocclusive disease in patients undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 25, 55-61
25. Hassan, M. et al. (2000) The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 25, 915-924
26. Vassal, G. et al. (1996) Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 37, 247-253
27. Kashyap, A. et al. (2002) Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol. Blood Marrow Transplant. 8, 493-500
28. Eberly, A.L. et al. (2008) Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 28, 1502-1510
29. Vassal, G. et al. (1990) Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 50, 6203-6207
30. Afify, Z. et al. (2000) Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. Bone Marrow Transplant. 25, 1087-1092
31. Brachet, C. et al. (2007) Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation. J. Pediatr. Hematol. Oncol. 29, 445-450
32. Maeda, N. et al. (2003) High-dose busulfan is a major risk factor for ovarian dysfunction in girls after stem cell transplantation. Clin. Pediatr. Endocrinol. 12, 13-18
33. Bakker, B. et al. (2004) Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant. 33, 1049-1056
34. Ljungman, P. et al. (1995) Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant. 15, 869-871
35. Peters, C. et al. (2013) Treosulfan for conditioning in children and adolescents before hematopoietic stem cell transplantation (HSCT). Biol. Blood Marrow Transplant. 19, S164
36. Heli, U. et al. (2012) Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. Eur. J. Haematol. 88, 87-88
37. Beier, R. et al. (2013) Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. Bone Marrow Transplant. 48, 491-501
38. Greystoke, B. et al. (2008) Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br. J. Haematol. 142, 257-262
39. Andersson, B.S. et al. (2000) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol. Blood Marrow Transplant. 6, 548-554
40. Grochow, L.B. et al. (1990) Busulfan disposition in children. Blood 75, 1723-1727
41. Gibbs, J.P. et al. (1999) Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab. Dispos. 27, 1466-1469
42. Lee, J.W. et al. (2012) Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol. Blood Marrow Transplant. 18, 944-950
43. Tran, H.T. et al. (2000) Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant. 26, 463-470
44. Czerwinski, M. et al. (1996) Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab. Dispos. 24, 1015-1019
45. Cooper, A.J.L. et al. (2008) Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction. Drug Metab. Dispos. 36, 1546-1552
46. Younis, I.R. et al. (2008) Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1. J. Pharmacol. Exp. Ther. 327, 770-776
47. Uppugunduri, C.R.S. et al. (2013) The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J. http://dx.doi.org/10.1038/tpj.2013.38 [Epub ahead of print]
48. Hassan, M. and Andersson, B.S. (2013) Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics 14, 75-87
49. Hassan, M. et al. (1994) Busulfan bioavailability. Blood 84, 2144-2150
50. Trame, M.N. et al. (2011) Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin. Cancer Res. 17, 6867-6877
51. Anderson, B.J. and Holford, N.H.G. (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25-36
52. Gibbs, J.P. et al. (1997) Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res. 57, 5509-5516
53. Savic, R.M. et al. (2013) Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol. Blood Marrow Transplant 19, 1608-1614
54. Johnson, L. et al. (2008) Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J. Clin. Pharmacol. 48, 1052-1062
55. Zwaveling, J. et al. (2008) Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther. Drug Monit. 30, 504-510
56. Abbasi, N. et al. (2011) Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J. Clin. Pharmacol. 51, 1429-1438
57. Srivastava, A. et al. (2004) Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104, 1574-1577
58. Krivoy, N. et al. (2012) Pharmacokinetic and pharmacogenetic analysis of oral busulfan in stem cell transplantation: prediction of poor drug metabolism to prevent drug toxicity. Curr. Drug Saf. 7, 211-217
59. Bonifazi, F. et al. (2013) Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. Haematologica 99, 172-179
60. Ten Brink, M.H. et al. (2013) Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. Pharmacogenet. Genomics 23, 675-683
61. Ten Brink, M.H. et al. (2013) Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics 14, 1683-1690
62. Poonkuzhali, B. et al. (2001) Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab. Dispos. 29, 264-267
63. Nath, C.E. et al. (2008) Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. Br. J. Clin. Pharmacol. 66, 50-59
64. Hassan, M. et al. (1993) Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother. Pharmacol. 33, 181-186
65. Buggia, I. et al. (1996) Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation, GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res. 16, 2083-2088
66. Nilsson, C. et al. (2003) The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 31, 429-435
67. Zwaveling, J. et al. (2005) Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant. 35, 17-23
68. Lai, W.K. et al. (1998) Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin. Chem. 44, 2506-2510
69. Cremers, S. et al. (2002) Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br. J. Clin. Pharmacol. 53, 386-389
70. Slattery, J.T. et al. (1995) Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 16, 31-42
71. Schechter, T. et al. (2007) Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 13, 307-314
72. Ljungman, P. et al. (1997) High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 20, 909-913
73. McCune, J.S. et al. (2002) Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 30, 167-173
74. Bolinger, A.M. et al. (2000) An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 25, 925-930
75. Bartelink, I.H. et al. (2009) Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol. Blood Marrow Transplant. 15, 231-241
76. Ansari, M. et al. (2013) Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther. Drug Monit. 36, 93-99
77. Bartelink, I.H. et al. (2014) Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric HCT: maintaining efficacy with less toxicity. Biol. Blood Marrow Transplant 20, 345-353
78. Hilger, R.A. et al. (1998) Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 42, 99-104
79. Scheulen, M.E. et al. (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin. Cancer Res. 6, 4209-4216
80. Beelen, D.W. et al. (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 35, 233-241
81. Nemecek, E.R. et al. (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol. Blood Marrow Transplant. 17, 341-350
82. Główka, F.K. et al. (2008) Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant. 42 (Suppl 2), S67-S70
83. Ten Brink, M.H. et al. (2014) Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. Ther. Drug Monit. [Epub ahead of print]
84. Główka, F.K. et al. (2007) Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J. Chromatogr. B 850, 569-574
85. Główka, F.K. et al. (2012) HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: pharmacokinetic application. J. Pharm. Biomed. Anal. 62, 105-113
86. De Jonge, M.E. et al. (2005) Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin. Pharmacokinet. 44, 147-173
87. Lindley, C. et al. (2004) Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs 15, 453-459
88. Bartelink, I.H. et al. (2008) Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 14, 88-98
89. Balasubramanian, P. et al. (2001) Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant. 28, 821-825
90. Nguyen, L. et al. (2004) I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 33, 979-987
91. Mürdter, T.E. et al. (2001) Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin. Chem. 47, 1437-1442
92. Bartelink, I.H. et al. (2012) Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin. Pharmacokinet. 51, 331-345
93. Shimoni, A. et al. (2012) Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone Marrow Transplant. 47, 1274-1282
94. Anurathapan, U. et al. (2013) Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. Biol. Blood Marrow Transplant. 19, 1259-1262
95. Hussein, A.A. et al. (2013) Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatr. Blood Cancer 60, 1345-1349
96. Hamidieh, A. et al. (2012) The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience. J. Pediatr. Hematol. Oncol. 34, 101-107
97. Law, J. et al. (2012) Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol. Blood Marrow Transplant. 18, 1656-1663
98. Styczynski, J. et al. (2011) A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant. 46, 790-799
99. McPherson, M.E. et al. (2011) Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 46, 27-33
100. Gaziev, J. et al. (2010) Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 115, 4597-4604
101. Lehmberg, K. et al. (2014) Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. Haematologica 99, 180-184
102. Corker, E. et al. (2012) Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia. Br. J. Haematol. 159, 104-106
103. Paci, A. et al. (2012) Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther. Drug Monit. 34, 198-208
104. Kellogg, M.D. et al. (2005) Tandem mass spectrometry method for the quantification of serum busulfan. Ther. Drug Monit. 27, 625-629
105. Quernin, M.-H. et al. (1998) Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. J. Chromatogr. B 709, 47-56
106. Bleyzac, N. et al. (2000) Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J. Chromatogr. B 742, 427-432